Literature DB >> 31079270

A Unique Presentation of Infantile-Onset Colitis and Eosinophilic Disease without Recurrent Infections Resulting from a Novel Homozygous CARMIL2 Variant.

Alina Kurolap1,2, Orly Eshach Adiv2,3, Liza Konnikova4,5,6, Lael Werner7,8, Claudia Gonzaga-Jauregui9, Maya Steinberg1, Vanessa Mitsialis5,6, Adi Mory1, Moran Y Nunberg7,8, Sarah Wall5, Ron Shaoul2,3, John D Overton9, Alan R Shuldiner9, Yaniv Zohar2,10, Tamar Paperna1, Scott B Snapper5,6,11, Dror S Shouval7,8, Hagit Baris Feldman12,13.   

Abstract

PURPOSE: This study aimed to characterize the clinical phenotype, genetic basis, and consequent immunological phenotype of a boy with severe infantile-onset colitis and eosinophilic gastrointestinal disease, and no evidence of recurrent or severe infections.
METHODS: Trio whole-exome sequencing (WES) was utilized for pathogenic variant discovery. Western blot (WB) and immunohistochemical (IHC) staining were used for protein expression analyses. Immunological workup included in vitro T cell studies, flow cytometry, and CyTOF analysis.
RESULTS: WES revealed a homozygous variant in the capping protein regulator and myosin 1 linker 2 (CARMIL2) gene: c.1590C>A; p.Asn530Lys which co-segregated with the disease in the nuclear family. WB and IHC analyses demonstrated reduced protein levels in patient's cells compared with controls. Moreover, comprehensive immunological workup revealed severely diminished blood-borne regulatory T cell (Treg) frequency and impaired in vitro CD4+ T cell proliferation and Treg generation. CyTOF analysis showed significant shifts in the patient's innate and adaptive immune cells compared with healthy controls and ulcerative colitis patients.
CONCLUSIONS: Pathogenic variants in CARMIL2 have been implicated in an immunodeficiency syndrome characterized by recurrent infections, occasionally with concurrent chronic diarrhea. We show that CARMIL2-immunodeficiency is associated with significant alterations in the landscape of immune populations in a patient with prominent gastrointestinal disease. This case provides evidence that CARMIL2 should be a candidate gene when diagnosing children with very early onset inflammatory and eosinophilic gastrointestinal disorders, even when signs of immunodeficiency are not observed.

Entities:  

Keywords:  CARMIL2; RLTPR; immunodeficiency; infantile colitis; very early onset inflammatory bowel disease

Mesh:

Substances:

Year:  2019        PMID: 31079270     DOI: 10.1007/s10875-019-00631-6

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  30 in total

1.  dbSNP: the NCBI database of genetic variation.

Authors:  S T Sherry; M H Ward; M Kholodov; J Baker; L Phan; E M Smigielski; K Sirotkin
Journal:  Nucleic Acids Res       Date:  2001-01-01       Impact factor: 16.971

Review 2.  Leukotrienes.

Authors:  Marc Peters-Golden; William R Henderson
Journal:  N Engl J Med       Date:  2007-11-01       Impact factor: 91.245

3.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm.

Authors:  Prateek Kumar; Steven Henikoff; Pauline C Ng
Journal:  Nat Protoc       Date:  2009-06-25       Impact factor: 13.491

4.  MutationTaster2: mutation prediction for the deep-sequencing age.

Authors:  Jana Marie Schwarz; David N Cooper; Markus Schuelke; Dominik Seelow
Journal:  Nat Methods       Date:  2014-04       Impact factor: 28.547

5.  CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes.

Authors:  Amy A Caudy; Sreelatha T Reddy; Talal Chatila; John P Atkinson; James W Verbsky
Journal:  J Allergy Clin Immunol       Date:  2006-12-27       Impact factor: 10.793

6.  The lymphoid lineage-specific actin-uncapping protein Rltpr is essential for costimulation via CD28 and the development of regulatory T cells.

Authors:  Yinming Liang; Margot Cucchetti; Romain Roncagalli; Tadashi Yokosuka; Aurélie Malzac; Elodie Bertosio; Jean Imbert; Isaac J Nijman; Miloslav Suchanek; Takashi Saito; Christoph Wülfing; Bernard Malissen; Marie Malissen
Journal:  Nat Immunol       Date:  2013-06-23       Impact factor: 25.606

Review 7.  Structural analysis of leucine-rich-repeat variants in proteins associated with human diseases.

Authors:  N Matsushima; N Tachi; Y Kuroki; P Enkhbayar; M Osaki; M Kamiya; R H Kretsinger
Journal:  Cell Mol Life Sci       Date:  2005-12       Impact factor: 9.261

8.  Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome.

Authors:  Gulbu Uzel; Elizabeth P Sampaio; Monica G Lawrence; Amy P Hsu; Mary Hackett; Morna J Dorsey; Richard J Noel; James W Verbsky; Alexandra F Freeman; Erin Janssen; Francisco A Bonilla; Joseph Pechacek; Prabha Chandrasekaran; Sarah K Browne; Anahita Agharahimi; Ahmed M Gharib; Sara C Mannurita; Jae Joon Yim; Eleonora Gambineri; Troy Torgerson; Dat Q Tran; Joshua D Milner; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2013-03-25       Impact factor: 10.793

9.  A method and server for predicting damaging missense mutations.

Authors:  Ivan A Adzhubei; Steffen Schmidt; Leonid Peshkin; Vasily E Ramensky; Anna Gerasimova; Peer Bork; Alexey S Kondrashov; Shamil R Sunyaev
Journal:  Nat Methods       Date:  2010-04       Impact factor: 28.547

10.  An integrated map of genetic variation from 1,092 human genomes.

Authors:  Goncalo R Abecasis; Adam Auton; Lisa D Brooks; Mark A DePristo; Richard M Durbin; Robert E Handsaker; Hyun Min Kang; Gabor T Marth; Gil A McVean
Journal:  Nature       Date:  2012-11-01       Impact factor: 49.962

View more
  6 in total

1.  CARMIL2-related immunodeficiency manifesting with photosensitivity.

Authors:  Leila H Shayegan; Maria C Garzon; Kimberly D Morel; Rachel Borlack; Patricia M Vuguin; Kara G Margolis; Yesim Y Demirdag; Elaine M Pereira; Christine T Lauren
Journal:  Pediatr Dermatol       Date:  2020-04-27       Impact factor: 1.588

2.  Exogenous interleukin-2 can rescue in-vitro T cell activation and proliferation in patients with a novel capping protein regulator and myosin 1 linker 2 mutation.

Authors:  O Toker; M Berger; O Shamriz; A J Simon; A Lev; O Megged; O Ledder; E Picard; L Joseph; V Molho-Pessach; Y Tal; P Millman; M Slae; R Somech
Journal:  Clin Exp Immunol       Date:  2020-04-18       Impact factor: 4.330

3.  Complex Muco-cutaneous Manifestations of CARMIL2-associated Combined Immunodeficiency: A Novel Presentation of Dysfunctional Epithelial Barriers.

Authors:  Giuseppe Marangi; Simone Garcovich; Gabriele Di Sante; Daniela Orteschi; Silvia Frangella; Franco Scaldaferri; Maurizio Genuardi; Ketty Peris; Fiorella Gurrieri; Marcella Zollino
Journal:  Acta Derm Venereol       Date:  2020-01-23       Impact factor: 3.875

4.  A Novel Pathogenic Variant in CARMIL2 (RLTPR) Causing CARMIL2 Deficiency and EBV-Associated Smooth Muscle Tumors.

Authors:  Jennifer R Yonkof; Ajay Gupta; Cesar M Rueda; Shamlal Mangray; Benjamin T Prince; Hemalatha G Rangarajan; Mohammad Alshahrani; Elizabeth Varga; Timothy P Cripe; Roshini S Abraham
Journal:  Front Immunol       Date:  2020-06-18       Impact factor: 7.561

Review 5.  Novel Genetic Discoveries in Primary Immunodeficiency Disorders.

Authors:  Margaret T Redmond; Rebecca Scherzer; Benjamin T Prince
Journal:  Clin Rev Allergy Immunol       Date:  2022-01-12       Impact factor: 10.817

6.  Novel CARMIL2 loss-of-function variants are associated with pediatric inflammatory bowel disease.

Authors:  Mara Cananzi; Aleixo M Muise; Luca Bosa; Vritika Batura; Davide Colavito; Karoline Fiedler; Paola Gaio; Conghui Guo; Qi Li; Antonio Marzollo; Claudia Mescoli; Ryusuke Nambu; Jie Pan; Giorgio Perilongo; Neil Warner; Shiqi Zhang; Daniel Kotlarz; Christoph Klein; Scott B Snapper; Thomas D Walters; Alberta Leon; Anne M Griffiths
Journal:  Sci Rep       Date:  2021-03-15       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.